[go: up one dir, main page]

WO2011126352A3 - Anti-tuberculosis preparation based on an inclusion complex of cyclodextrin with rifampicin and a method for the preparation thereof - Google Patents

Anti-tuberculosis preparation based on an inclusion complex of cyclodextrin with rifampicin and a method for the preparation thereof Download PDF

Info

Publication number
WO2011126352A3
WO2011126352A3 PCT/KZ2011/000004 KZ2011000004W WO2011126352A3 WO 2011126352 A3 WO2011126352 A3 WO 2011126352A3 KZ 2011000004 W KZ2011000004 W KZ 2011000004W WO 2011126352 A3 WO2011126352 A3 WO 2011126352A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
rifampicin
cyclodextrin
tuberculosis
inclusion complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KZ2011/000004
Other languages
French (fr)
Russian (ru)
Other versions
WO2011126352A2 (en
Inventor
Кунназ Баймухановна МУРЗАГУЛОВА
Турарбек Амирханович РАКИШ
Марина Емельяновна КИМ
Калдыбай Джайловович ПРАЛИЕВ
Кайрат Мирзасалимович БЕКЕТО
Жанболат Илесович РУСТЕМБЕКОВ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Joint-Stock Co "ab Bekturov's Institute Of Chemical Sciences"
ROMAT PHARMACEUTICAL Co Ltd
Original Assignee
Joint-Stock Co "ab Bekturov's Institute Of Chemical Sciences"
ROMAT PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joint-Stock Co "ab Bekturov's Institute Of Chemical Sciences", ROMAT PHARMACEUTICAL Co Ltd filed Critical Joint-Stock Co "ab Bekturov's Institute Of Chemical Sciences"
Priority to EA201201098A priority Critical patent/EA201201098A1/en
Publication of WO2011126352A2 publication Critical patent/WO2011126352A2/en
Publication of WO2011126352A3 publication Critical patent/WO2011126352A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An anti-tuberculosis preparation based on an inclusion complex of cyclodextrin with rifampicin and a method for the preparation thereof. The invention relates to the pharmaceutical industry and may be utilized in medical institutions for the treatment of tuberculosis. Using the claimed ratio of components, the preparation, which consists of an inclusion complex of cyclodextrin with rifampicin in a molar ratio of 1:1, and granulated isoniazid with a pH-sensitive polymer of auxiliary substances - sweetener, a disintegrator, a hepatoprotector, an antioxidant and a mixture of lubricating substances - calcium or magnesium stearate and aerosil, makes it possible to minimize the first stage of absorption of the preparation while maintaining the bio-availability of the rifampicin with low toxicity (LD50 5000 mg/kg), and it can be used not only for adults, but also for children.
PCT/KZ2011/000004 2010-04-07 2011-03-29 Anti-tuberculosis preparation based on an inclusion complex of cyclodextrin with rifampicin and a method for the preparation thereof Ceased WO2011126352A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201201098A EA201201098A1 (en) 2010-04-07 2011-03-29 ANTITUBERCULAR PREPARATION BASED ON THE COMPLEX FOR INCLUSION OF CYCLODEXTRIN WITH RIFAMPICIN AND THE METHOD OF ITS OBTAINING

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KZ2010/0417.1 2010-04-07
KZ20100417 2010-04-07

Publications (2)

Publication Number Publication Date
WO2011126352A2 WO2011126352A2 (en) 2011-10-13
WO2011126352A3 true WO2011126352A3 (en) 2011-12-01

Family

ID=44763441

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KZ2011/000004 Ceased WO2011126352A2 (en) 2010-04-07 2011-03-29 Anti-tuberculosis preparation based on an inclusion complex of cyclodextrin with rifampicin and a method for the preparation thereof

Country Status (2)

Country Link
EA (1) EA201201098A1 (en)
WO (1) WO2011126352A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041284A1 (en) * 2002-10-28 2004-05-21 Council Of Scientific And Industrial Research Inclusion complex of anti-tubercular rifampicin with beta-cyclodextrin or 2-hydroxypropyl beta-cyclodextrin and a process for producing the same
RU2240795C2 (en) * 2000-08-09 2004-11-27 Панацея Биотек Лимитед Pharmaceutical compositions of antituberculosis medicinal agents and method for their preparing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2240795C2 (en) * 2000-08-09 2004-11-27 Панацея Биотек Лимитед Pharmaceutical compositions of antituberculosis medicinal agents and method for their preparing
WO2004041284A1 (en) * 2002-10-28 2004-05-21 Council Of Scientific And Industrial Research Inclusion complex of anti-tubercular rifampicin with beta-cyclodextrin or 2-hydroxypropyl beta-cyclodextrin and a process for producing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Instruktsiya po primeneniju lekarstvennogo sredstva dlya spetsialistov RIZEF 150/150", INSTRUKTSIYA PO PRIMENENIJU LEKARSTVENNOGO SREDSTVA DLYA SPETSIALISTOV RIZEF 150/150, 5 March 2008 (2008-03-05), pages 1, Retrieved from the Internet <URL:http.//www.zakon-online.com/Admin/login.aspx?docid=2487034> [retrieved on 20110802] *
"Promyshlennaya tekhnologiya lekarstv", KHARKOV, IZDATELSTVO NFAU, MTK-KNIGA, vol. 2, 2002, pages 330 - 336 *

Also Published As

Publication number Publication date
EA201201098A1 (en) 2013-03-29
WO2011126352A2 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
WO2006086107A3 (en) Methods and compositions for minimizing accrual of inhalable insulin in the lungs
WO2008092084A3 (en) Injectable non-aqueous suspension with high concentration of therapeutic agent
WO2007123995A3 (en) Camptothecin-analog with a novel, “flipped” lactone-stable, e-ring and methods for making and using same
WO2007149406A8 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
WO2010067078A8 (en) 3,6-disubstituted xanthylium salts
UA93673C2 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
JO2932B1 (en) Pegylated insulin lispro compounds
WO2011008495A3 (en) Arginase formulations and methods
WO2008128049A3 (en) Tetrahydrobiopterin compositions and methods of measuring
WO2007127273A3 (en) Methods and compositions for altering cell function
EP1611880A3 (en) Pharmaceutical formulations for the safe administration of drugs used in the treatment of drug addiction
WO2011019617A3 (en) Vitamin d3 and analogs thereof for treating alopecia
WO2007133751A3 (en) Base-stabilized polyorthoester formulations
WO2008022974A3 (en) Anti-diabetes composition containing chicoric acid and/or one of the metabolites thereof
WO2011081373A3 (en) Method for preparing highly pure anhydrous crystalline docetaxel
WO2010099542A3 (en) Formulations of atp and analogas of atp
MX2010004556A (en) Pharmaceutical formulation of clavulanic acid.
WO2008128191A3 (en) Oral cephalotaxine dosage forms
WO2007130509A3 (en) Pyrroloquinoline quinones and use thereof
WO2010021750A3 (en) Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
WO2008027533A3 (en) Personal care compositions comprising pear seed extract
WO2009048940A3 (en) Diacerein pharmaceutical formulations
WO2008087774A1 (en) Antioxidant
WO2011126352A3 (en) Anti-tuberculosis preparation based on an inclusion complex of cyclodextrin with rifampicin and a method for the preparation thereof
WO2007110709A3 (en) Formulations of tipifarnib for intravenous administration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11766203

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 201201098

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11766203

Country of ref document: EP

Kind code of ref document: A2